不同药物治疗首发精神分裂症疗效和安全性分析  

Efficacy and Safety Analysis of Different Drugs in Treatment of Primary Schizophrenia

作　　者：李娟[1] LI Juan(Chengdu Fourth People's Hospital,Sichuan Chengdu 610000)

机构地区：[1]成都市第四人民医院,四川成都610000

出　　处：《按摩与康复医学》2020年第21期58-59,63,共3页Chinese Manipulation and Rehabilitation Medicine

摘　　要：目的:对氨磺必利与利培酮治疗首发精神分裂症的临床疗效与安全性进行分析。方法:选取2018年1月~2019年1月本院收治的首发精神分裂症患者77例,随机分为对照组37例与观察组40例。对照组服用利培酮,观察组服用氨磺必利,对比两组患者治疗优良率、不良反应发生率、临床症状量表评分。结果:观察组治疗优良率高于对照组(P<0.05),总不良反应发生率低于对照组(P<0.05),临床症状量表评分低于对照组(P<0.05)。结论:氨磺必利治疗首发精神分裂症的疗效较好,且具有较高的安全性,可在临床推广。Objective: To analyze the clinical efficacy and safety of sulfapiride and risperidone in the treatment of first-episode schizophrenia.Methods: From January 2018~January 2019,77 patients with first-episode schizophrenia were randomly divided into control group 37 cases and observation group 40 cases.The control group was treated with risperidone and the observation group was treated with sulfapiride.The excellent and good rate of treatment, the incidence of adverse reactions and the score of clinical symptom scale were compared between the two groups.Results: The excellent rate of treatment in the experimental group was higher than that in the control group,(P<0.05), the incidence of total adverse reactions in the experimental group was lower than that in the control group(P<0.05), and the score of clinical symptom scale in the experimental group was lower than that in the control group(P<0.05).Conclusion: the efficacy of sulfamethoxazole in the treatment of first-episode schizophrenia is good, and it has high safety, which can be used in clinical practice.

关 键 词：氨磺必利 利培酮 首发精神分裂症 临床疗效 安全性 

分 类 号：R74[医药卫生—神经病学与精神病学]